Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael D. Otremba, M.D.

Concepts (67)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Cranial Fossa, Anterior12013130.460 Why?
Prisons120151610.450 Why?
Hospital Charges120153620.440 Why?
Otitis12012200.420 Why?
Mastoiditis12012340.410 Why?
Agammaglobulinemia120121670.370 Why?
Maxilla120134700.360 Why?
Skull Base Neoplasms120132840.340 Why?
Antibodies, Monoclonal, Murine-Derived120126930.330 Why?
Immunoglobulins, Intravenous120126520.300 Why?
Poverty1201526600.220 Why?
Developing Countries1201528150.210 Why?
Neoplasms, Unknown Primary120181040.150 Why?
Neck Dissection120181970.140 Why?
Papillomavirus Infections2201815870.140 Why?
Radiotherapy, Adjuvant2201817700.140 Why?
Patient Credit and Collection12015160.130 Why?
Salivary Gland Neoplasms120182980.120 Why?
Head and Neck Neoplasms2201827340.120 Why?
Carcinoma, Squamous Cell2201840340.110 Why?
Oropharyngeal Neoplasms120174770.100 Why?
Human Rights120153070.100 Why?
Lymph Node Excision1201812610.100 Why?
Parotid Neoplasms120131550.100 Why?
Lymphatic Metastasis1201829240.090 Why?
Chemotherapy, Adjuvant1201834790.090 Why?
Neoplasm, Residual120139730.080 Why?
SEER Program1201315080.080 Why?
Lymphoma1201318770.060 Why?
Immunologic Factors1201215800.050 Why?
Antirheumatic Agents1201213390.050 Why?
Kaplan-Meier Estimate3201865380.050 Why?
Neoplasm Staging32018110310.040 Why?
Chronic Disease1201291460.040 Why?
Arthritis, Rheumatoid1201237120.030 Why?
Neoplasm Recurrence, Local1201392390.030 Why?
Drug Therapy120174970.030 Why?
Treatment Outcome32018631140.030 Why?
Prognosis32018290630.030 Why?
Survival Rate22018127880.030 Why?
Propensity Score1201817810.020 Why?
Papillomaviridae1201711190.020 Why?
Proportional Hazards Models22018123540.020 Why?
Female620183801940.020 Why?
Middle Aged520182133830.020 Why?
Humans820187443430.020 Why?
Follow-Up Studies12012390500.020 Why?
Tomography, X-Ray Computed12013201290.020 Why?
Young Adult22013564300.020 Why?
Retrospective Studies42018774490.020 Why?
Sex Distribution1201322970.020 Why?
Male520183501180.020 Why?
Age Distribution1201329020.020 Why?
Combined Modality Therapy1201886420.020 Why?
Magnetic Resonance Imaging12013354210.020 Why?
Survival Analysis12018102520.020 Why?
Aged420181632800.020 Why?
Disease-Free Survival1201368950.010 Why?
Incidence12013209470.010 Why?
Infant, Newborn12013256250.010 Why?
Infant12013351360.010 Why?
Child, Preschool12013410060.010 Why?
Aged, 80 and over12013577760.000 Why?
United States12013698720.000 Why?
Child12013777090.000 Why?
Adolescent12013857810.000 Why?
Adult120132140550.000 Why?
Otremba's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (67)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.